Your browser doesn't support javascript.
loading
Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?
García Trevijano Cabetas, Macarena; Escario-Gómez, Miguel; González-Del Valle, Luis; Sobrino Jiménez, Carmen; Bilbao Gomez-Martino, Cristina; Romero-Garrido, José Antonio; Benedi-González, Juana; Espinosa Arranz, Enrique; Díaz Almirón, Mariana; Herrero Ambrosio, Alicia.
Afiliação
  • García Trevijano Cabetas M; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain macarena.garciatrevijano@salud.madrid.org.
  • Escario-Gómez M; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain.
  • González-Del Valle L; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain.
  • Sobrino Jiménez C; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain.
  • Bilbao Gomez-Martino C; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain.
  • Romero-Garrido JA; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain.
  • Benedi-González J; Pharmacy Department, Universidad Complutense de Madrid, Madrid, Comunidad de Madrid, Spain.
  • Espinosa Arranz E; Medical Oncology Department, La Paz University Hospital, Madrid, Spain.
  • Díaz Almirón M; Hospital Statistics Department, La Paz University Hospital, Madrid, Spain.
  • Herrero Ambrosio A; Hospital Pharmacy Department, La Paz University Hospital, Madrid, Spain.
Eur J Hosp Pharm ; 30(5): 268-272, 2023 09.
Article em En | MEDLINE | ID: mdl-34620687
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração Idioma: En Ano de publicação: 2023 Tipo de documento: Article